Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy, Safety, and Tolerability of Adjuvant GLS-1200 Topical Nasal Spray in the Prevention of Acute Rhinosinusitis Following Functional Endoscopic Sinus Surgery (FESS)

Next Previous
Trial Profile

Efficacy, Safety, and Tolerability of Adjuvant GLS-1200 Topical Nasal Spray in the Prevention of Acute Rhinosinusitis Following Functional Endoscopic Sinus Surgery (FESS)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quinine (Primary)
  • Indications Rhinosinusitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GeneOne Life Science

Most Recent Events

  • 10 Jan 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
  • 10 Jan 2023 Planned primary completion date changed from 1 Feb 2023 to 31 Dec 2023.
  • 10 Jan 2023 Planned initiation date changed from 1 Feb 2022 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top